SMi present their 4th annual conference on...

Biosimilars and Biobetters

Monday 24th & Tuesday 25th September 2012
Copthorne Tara Hotel, London

KEY SPEAKERS INCLUDE:

Laura McKinley
Director Worldwide Regulatory Strategy
Pfizer

Heinz Hänel
Director, Diabetes Division R&D Projects
Sanofi

Andrew Rankin
Head of Clinical Development
Teva Pharmaceuticals

Richard DiCicco
Chairman
Harvest Moon Pharmaceuticals USA, Inc

Ezogelin Oflazoglu
Senior Director and Senior Project Leader, MBV Biologics PPM
Merck Bioventures

Anne Dollard
Chief Patent Counsel, Deputy General Counsel
Takeda Pharmaceuticals

Paul Greenland
EMEA Director of Biosimilars and Proprietary Marketing
Hospira

Sandy Eisen
Chief Medical Officer, former CMO, Frontline Pharma Consulting
Teva Pharmaceuticals

Sreedhar Sagi
Risk Management Compliance Officer
Biopharmaceuticals Development
Sandoz

David Szymkowski
Senior Director, Research, Biotherapeutics
Xencor

WHY ATTEND THIS EVENT?

• Be informed of the latest news in biosimilar pipelines
• Take note of current and future developments in intellectual property and patent protection
• Be aware of the impact of recent guidelines issued by regulatory bodies such as the FDA and EMEA
• Discuss commercial and financial strategies
• Consider market access pathways and strategies
• Develop plans and methods for biosimilar and biobetter drug design and clinical testing

PLUS AN INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP

Wednesday 26th September 2012, Copthorne Tara Hotel, London

A critical review of US and EU legal framework for biosimilar products including practical examples for strategic development

Workshop Leader: Lincoln Tsang, Partner, Arnold and Porter LLP
8.30am to 12.30pm, 26th September 2012, Copthorne Tara Hotel, London

www.biosimilars-biobetters.co.uk
Register online and receive full information on all of SMi's conferences
Alternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
8.30 Registration and Coffee

9.00 Chairman’s opening remarks
Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals

9.10 Clinical approach to biosimilar development
• Pharmacokinetic studies of approved biosimilars
• Implementing comparative clinical trials
• Demonstrating therapeutic equivalence
• Submitting results to regulatory boards
Andrew Rankin, Head of Clinical Development, Teva Pharmaceuticals

9.50 Development of biosimilar monoclonal antibodies: opportunities and challenges
• Introduction to monoclonal biosimilars; are there any special requirements for the demonstration of biosimilarity?
• Biosimilars and monoclonals in Europe; progress since 2005
• The biosimilar monoclonal commercial opportunity
• Comparing the EU and US biosimilars laws and guidelines
• What are the key challenges for the clinical development, registration and commercialisation of biosimilar monoclonal antibodies
Sandy Eisen, Chief Medical Officer, former CMO, Frontline Pharma Consulting, Teva Pharmaceuticals

10.30 Morning Coffee

11.00 Safety in biosimilar development
• Importance of Phase III immunological trials, analytical expertise
• Identification of immunogenicity is dependent on various factors
• What impact does a modified immunological profile have on the clinical outcome?
Heinz Hänel, Director, Diabetes Division R&D Projects, Sanofi

11.40 Panel discussion: biosimilars vs. biobetters, so which is the better strategy?
• Initial return of investment (ROI)
• Gaining a competitive edge
• An accelerated approval process
• Innovator responses to the threat of competition
Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals
David Szymkowski, Senior Director, Research, Biotherapeutics, Xencor, Inc
Anne Dollard, Chief Patent Counsel, Deputy General Counsel, Takeda Pharmaceuticals

12.20 Networking lunch

1.50 The future of biosimilars in specific emerging markets
• Current biosimilar sales in specific emerging markets
• Issues for growth: changing regulatory requirements; protectionism; counter-detailing, MNC competition
• Future biosimilar sales in specific emerging markets
Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc

2.30 Minimising patent risk
• Why is patent risk higher for biopharmaceuticals than traditional small molecules?
• Identifying the patent risk
• Clearing the way - negotiating tactics
• Clearing the way - litigation tactics
Christopher Stothers, Partner, Arnold and Porter LLP

3.10 Afternoon Tea

3.40 Marketing Biosimilars in the EU
• Overview of the developing Biosimilar business in EU
• Key learnings in the early markets
• Nivestim: a case study of a Biosimilar GCSF
• Future opportunities and challenges
Paul Greenwood, EMEA Director of Biosimilars and Proprietary Marketing, Hospira

4.20 Global market analysis of follow on biologics
• Opportunities for long term growth
• Competition across emerging and established markets
• Transition from monopoly to oligopoly
• Innovator responses to competitor threats
Peter Wittner, Senior Consultant, Interpharm Consultancy

5.00 Chairman’s Closing Remarks and Close of Day One

Who should attend this conference?
You should attend this event if you are a Director, Area Head, CSO, or VP from within the Pharmaceutical or Healthcare industry with responsibilities in the following areas:

- Analytics
- Business Development
- Corporate Development Strategy
- Commercial Affairs
- Intellectual Property
- Marketing & Sales
- Medical Affairs
- New Product Development
- Legal Affairs
- CMC
- Preclinical and Clinical Development
- Product Development
- Regulatory Affairs
- Pricing and Reimbursement
- Research and Development
- Biologic Production
- Quality Assurance
- Scientific Affairs
- Strategic Planning
- Strategic Sourcing

SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMI offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
8.30  Re-registration and Coffee

9.00  Chairman’s opening remarks  
David Szymkowski, Senior Director, Research, Biotherapeutics, Xencor, Inc

**Drug Design**

9.10  Generating a biosuperiors pipeline through Fc engineering: a low-risk approach to improving the performance of therapeutic antibodies  
- Advantages and disadvantages of developing biosuperior vs. biosimilar biologics
- Strategies to improve half-life and potency
- Multiple case studies of antibodies and Fc fusion therapeutics will be presented  
David Szymkowski, Senior Director, Research, Biotherapeutics, Xencor, Inc

9.50  Forecasting the future of biosimilars  
- Branded biologics facing patent expiry
- Opportunities for biosimilar developers
- Varying results across geographic regions
- Who decides the fate of individual medications?  
Ori Hershkovitz, Partner and Head of Pharmaceutical Research, Sphera Global Healthcare Fund

10.00  Methods for biobetter development  
- Pegylation for less frequent injections
- Ultra potent antibodies and ligand traps
- Bispecific antibodies for dual activity
- Glycoengineering to increase potency  
Steve Brocchini, CSO, PolyTherics Ltd

11.10  Methods for determining biosimilarity  
- Side-by-side comparison with the original product
- Variations in structure
- Differing impurity profiles
- Foreign proteins and immunogenicity  
Harvinder Popli, Director, Corporate Development Ranbaxy Labs

12.20  Networking lunch

1.50  **KEYNOTE ADDRESS**  
**Variations in global regulatory strategy for biosimilars**  
- Regulations outside Europe, Japan and the U.S.
- EMEA approval in Europe
- MHLW approval in Japan
- FDA and the lack of approval in the U.S.  
Laura McKinley, Director Worldwide Regulatory Strategy, Pfizer

2.30  **Biosimilars Safety: Experience till date**  
- Uptake of Biosimilars (experience of one company)
- Pharmacovigilance of Biologics (incl. Biosimilars)
- Risk Management Plans
- Managing patients & physicians concerns  
Sreedhar Sagi, Risk Management Compliance Officer, Biopharmaceuticals Development, Sandoz

3.10  Afternoon Tea

3.40  **Case Study: Biferonex, a biosimilar of interferon beta-1a, and an effective treatment for multiple sclerosis**  
- Clinical testing for EMEA approval
- Devising a marketing authorisation application (MAA)
- Submission of documentation for the EMEA
- Managing the regulatory review process through to approval  
Invitation to: Conrad Savoy, CEO, Biopartners GmbH

4.20  **Innovation in generics: is it applicable?**  
- Generic market: Patent expiration of a host of Blockbuster drugs in the next 5 years versus austerity measures through Europe in the health sector
- Current market scenario and expected health measures: increase need and Limited resources
- Innovation in Generics, a way to maintain the growth
- Innovation: Inside/Outside the Company, Organization, Products and Services  
Nicola Travierso, General Manager, NTC SRL

5.00  Chairman’s Closing Remarks and Close of Day Two

---

**Regulatory Matters and Approval Processes**

**1.50  KEYNOTE ADDRESS**  
**Variations in global regulatory strategy for biosimilars**  
- Regulations outside Europe, Japan and the U.S.
- EMEA approval in Europe
- MHLW approval in Japan
- FDA and the lack of approval in the U.S.  
Laura McKinley, Director Worldwide Regulatory Strategy, Pfizer

**2.30  BIOSIMILARS SAFETY: EXPERIENCE TILL DATE**  
- Uptake of Biosimilars (experience of one company)
- Pharmacovigilance of Biologics (incl. Biosimilars)
- Risk Management Plans
- Managing patients & physicians concerns  
Sreedhar Sagi, Risk Management Compliance Officer, Biopharmaceuticals Development, Sandoz

**3.10  AFTERNOON TEA**

**3.40  CASE STUDY: BIFERONEX, A BIOSIMILAR OF INTERFERON BETA-1A, AND AN EFFECTIVE TREATMENT FOR MULTIPLE SCLEROSIS**  
- Clinical testing for EMEA approval
- Devising a marketing authorisation application (MAA)
- Submission of documentation for the EMEA
- Managing the regulatory review process through to approval  
Invitation to: Conrad Savoy, CEO, Biopartners GmbH

**4.20  INNOVATION IN GENERICS: IS IT APPLICABLE?**  
- Generic market: Patent expiration of a host of Blockbuster drugs in the next 5 years versus austerity measures through Europe in the health sector
- Current market scenario and expected health measures: increase need and Limited resources
- Innovation in Generics, a way to maintain the growth
- Innovation: Inside/Outside the Company, Organization, Products and Services  
Nicola Travierso, General Manager, NTC SRL

**5.00  CHAIRMAN’S CLOSING REMARKS AND CLOSE OF DAY TWO**

---

fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711

Supported by

---
A critical review of US and EU legal framework for biosimilar products including practical examples for strategic development

Workshop Leaders:
Lincoln Tsang, Partner, Arnold and Porter LLP
In association with

Overview of workshop
This workshop will discuss the regulatory framework for biosimilars in the US and EU including the issues concerning exclusivity and freedom-to-operate. Specifically, the workshop will cover:

- Current legal interpretations of the regulatory standard for approving a biosimilar product
- Data and patent exclusivity rights arising from consideration for approval of biosimilars
- Product substitution and interchangeability
- Safety assessment
- Impact of legal considerations on commercialisation

Programme
8.30 Registration & Coffee
9.00 Introductions and workshop overview
9.10 Anticipated US Regulatory Approval Pathway (the Biologics Price Competition and Innovation Act [BPCIA]) and the EMA Regulatory Framework
- definition of a biologic and biosimilar
- demonstrating biosimilarity
- product substitution and interchangeability
- data requirements
- exclusivity
- "bio-betters"
10.10 Patent Process under the BPCIA
- Timing and processes for resolution of patent disputes
11.10 Coffee Break
11.30 Impact on Commercialization
- Seizing licensing opportunities
- Market advantages
- Competitive landscape in emerging markets
12.30 Close of workshop

About the workshop hosts
Lincoln Tsang is a partner in the London office of Arnold & Porter LLP. His practice focuses on both contentious and non-contentious EU regulatory and compliance matters. Previously, he was head of biologicals/biotechnology of the UK Regulatory Authority and advisor to European Medicines Agency, European Commission, Council of Europe, World Health Organisation. Currently, he serves as Commissioner of the British Pharmacopoeia Commission where he co-chairs the biologicals expert group and the nomenclature committee.

Daniel Kracov is a partner and heads the FDA & Healthcare practice where he assists clients in negotiating the challenges relating to the development, approval and marketing of drugs, biologics, and medical devices. He also handles a wide variety of compliance and enforcement matters. Mr. Kracov is also widely recognized for his experience in biomedical product-related public policy matters, including Congressional investigations and legislative strategies. He currently serves as Chair of the Food and Drug Law Institute’s Drugs and Biologies Committee. His capabilities in strategic advice and crisis management have been widely recognized, including by Chambers, Washingtonian magazine, Best Lawyers, and the Legal Times list of the Top 10 FDA Lawyers.

Dr. David Marsh is co-chair of Arnold & Porter’s intellectual property practice. He focuses extensively on intellectual property counseling, interferences, inter partes and ex parte reexaminations, and patent procurement, including in the biotechnology, business methods, chemical, clothing, computer media, consumer products, and medical device areas. He has argued multiple matters before the United States Patent and Trademark Office’s Board of Patent Appeals and Interferences. He also manages multiple European Opposition proceedings, and represents clients in patent and other intellectual property litigation and dispute resolution proceedings.

About Arnold and Porter LLP
Arnold & Porter LLP, an 800 lawyer firm with offices in the US and Europe, assists clients around the world in the full range of life sciences transactions, litigation, and regulatory issues. For over six decades, our team of more than 75 Life Sciences attorneys -- including lawyers based in London and Washington, D.C. -- has advised companies large and small throughout every stage of the product life cycle.
<table>
<thead>
<tr>
<th>Month</th>
<th>April</th>
<th>May</th>
<th>June</th>
<th>July</th>
<th>August</th>
<th>September</th>
<th>October</th>
<th>November</th>
<th>December</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>15-16</td>
<td>14-15</td>
<td>11-12</td>
<td>21-22</td>
<td>20-21</td>
<td>17-18</td>
<td>8-9</td>
<td>5-6</td>
<td>3-4</td>
</tr>
<tr>
<td></td>
<td>Asthma &amp; COPD</td>
<td>Strategic Advertising &amp; Branding Management</td>
<td>Social Media in the Pharmaceutical Industry</td>
<td>ADMET</td>
<td>Social Media in the Pharmaceutical Industry</td>
<td>Next Generation Sequencing</td>
<td>Biobanking</td>
<td>Cell Based Assays</td>
<td>Cold Chain Distribution</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cancer Vaccines</td>
<td>BioBanking</td>
<td>Clinical Trials in CNS</td>
<td>5-6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Biologics and Biobetters</td>
<td>26-27</td>
<td>12-13</td>
<td>21-22</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>KOL Knowledge Leaders</td>
<td>KOL Management and MSL Best Practice</td>
<td>22-23</td>
<td>3-4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pain Therapeutics</td>
<td>Pain Therapeutics</td>
<td>BioBanking</td>
<td>29-30</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ADC Summit 2012</td>
<td>Clinical Trials in CNS</td>
<td>11-12</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ADC Summit 2012</td>
<td>ADC Summit 2012</td>
<td>BioBanking</td>
<td>29-30</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BioBanking</td>
<td>BioBanking</td>
<td>European Pharmaceutical Pricing &amp; Remuneration</td>
<td>22-23</td>
</tr>
</tbody>
</table>

All conferences take place in central London, UK – unless indicated otherwise in brackets.
DELEGATE DETAILS

Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: 
Surname: 
Job Title: 
Department/Division: 
Company/Organisation: 
Email: 
Address: 
Town/City: 
Post/Zip Code: 
Country:
Direct Tel: 
Direct Fax: 
Switchboard: 
Mobile: 
Signature: 
Date: 

ACCOUNTS DEPT

Title: 
Surname: 
Email: 
Address (if different from above):
Town/City: 
Post/Zip Code: 
Country:
Direct Tel: 
Direct Fax: 

Terms and Conditions of Booking

Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then card details will be required and payment taken before entry to the event. Bookings within 7 days of the event require payment on booking. Access to the Document Portal will not be given until payment has been received.

Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not share a place at an event. Please make separate bookings for each delegate.

Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the fee less a £25 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regrettably cancellation after this time cannot be accepted. We will however provide the conference documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed on the Document Portal unless a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regrettably cancellation after this time cannot be accepted. We will however provide the conference documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason, then we will make a full refund immediately, but disclaim any further liability.

Alternations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.

Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here (*) we may also share your data with third parties offering complimentary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager database.manager@smi-online.co.uk or visit our website www.smi-online.co.uk updates quoting the URN as detailed above your address on the attached letter.

VAT

VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document Portal/paper copy documentation Price Total

GROUP DISCOUNTS AVAILABLE

I would like to attend: (Please tick as appropriate) Fee Total

□ Conference & 2 Workshops £2597.00 + VAT £3116.40
□ Conference & 1 Workshop £1998.00 + VAT £2397.60
□ Conference only £1399.00 + VAT £1678.80
□ 1 Workshop only £999.00 + VAT £1198.80
□ 2 Workshops £1198.00 + VAT £1477.60
Promotional Literature Distribution

□ Distribution of your company’s promotional literature to all conference attendees £999.00 + VAT £1198.80

Early Bird Discount

□ Book by 31st May 2012 to receive a £300 off the conference price

BOOKING FORM FOR BIOSIMILARS AND BIOBETTERS

CONFERENCE: Monday 5th and Tuesday 6th March 2012, Copthorne Tara Hotel, London, UK

Workshops: Wednesday 7th March 2012, London, UK

4 WAYS TO REGISTER

www.biosimilars-biobetters.co.uk

FAX your booking form to +44 (0) 870 9090 712

PHONE on +44 (0) 870 9090 711

POST your booking form to: Events Team, SMi Group Ltd, Great Guildford Business Square, 30 Great Guildford Street London, SE1 0HS, UK

EARLY BIRD

□ Book by 31st May 2012 to receive a £300 off the conference price

CONFERENCE PRICES

I would like to attend: (Please tick as appropriate) Fee Total

□ Conference & 2 Workshops £2597.00 + VAT £3116.40
□ Conference & 1 Workshop £1998.00 + VAT £2397.60
□ Conference only £1399.00 + VAT £1678.80
□ 1 Workshop only £999.00 + VAT £1198.80
□ 2 Workshops £1198.00 + VAT £1477.60

PROMOTIONAL LITERATURE DISTRIBUTION

□ Distribution of your company’s promotional literature to all conference attendees £999.00 + VAT £1198.80

VANUE

Copthorne Tara Hotel, Scarsdale Place, Kensington, London W8 5SR

□ Please contact me to book my hotel

Alternatively call us on +44 (0) 870 9090 711, email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk

SMi Group Ltd, PO Box 80, London EC2A 9BN

VAT

VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document Portal/paper copy documentation Price Total

□ Access to the conference documentation on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy (or only £300 if ordered with the Document Portal) £499.00 + VAT £499.00

PAYMENT

Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-043 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment:

□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LLOYDB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18

□ Cheque We can only accept Sterling cheques drawn on a UK bank.

□ Credit Card □ Visa □ MasterCard □ American Express

All credit card payments will be subject to standard credit card charges.

Card No: 
Expiry Date: 
CVV Number: 

Cardholder’s Name: 

Signature: 
Date: 

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk